The utilization of medical information is a pressing issue for pharmaceutical companies, particularly from the perspective of pharmacovigilance applications. There are currently some types of adverse reaction risks that cannot be detected in Japan but can be detected in Europe and the U.S.A. because secondary use of medical information is possible there. To remedy this lag, it is essential that we update the framework of Japan's system. We must create medical information standards that allow public use and we must define a level of quality control.